Merck & Co.’s cancer drug Keytruda (pembrolizumab) was superior in treating patients of advanced melanoma in phase III clinical trials compared to Bristol-Myers Squibb Co.’s Yervoy (ipilimumab). Keytruda is in a class of cancer drugs known as PD-1 inhibitors. It is currently approved for the treatment of unresectable or metastatic melanoma, and in patients whose disease has progressed after the use of the standard treatment, Yervoy. The positive results of the latest trial of Keytruda is good news for the large number of patients worldwide with skin cancer. Melanoma is the deadliest form of skin cancer because it can be ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.